T-Type voltage gated calcium channels: a target in breast cancer?
Anamika Bhargava1, Sumit Saha2
1Ion Channel Biology Lab, Department of Biotechnology, Indian Institute of Technology Hyderabad (IITH), Kandi, Telangana, 502285, India. abhargava@iith.ac.in.
Purpose:
The purpose of this review article is to discuss the potential of T-type voltage gated calcium channels (VGCCs) as drug targets in breast cancer. Breast cancer, attributable to the different molecular subtypes, has a crucial need for therapeutic strategies to counter the mortality rate. VGCCs play an important role in regulating cytosolic free calcium levels which regulate cellular processes like tumorigenesis and cancer progression. In the last decade, T-type VGCCs have been investigated in breast cancer proliferation. Calcium channel blockers, in general, have shown an anti-proliferative and cytotoxic effects. T-type VGCC antagonists have shown growth inhibition owing to the inhibition of CaV3.2 isoform. CaV3.1 isoform has been indicated as a tumour-suppressor gene candidate and is reported to support anti-proliferative and apoptotic activity in breast cancer. The distribution of T-type VGCC isoforms in different breast cancer molecular subtypes is diverse and needs to be further investigated. The role of T-type VGCCs in breast cancer migration, metastasis and more importantly in epithelial to mesenchymal transition (EMT) is yet to be elucidated. In addition, interlaced therapy, using a combination of chemotherapy drugs and T-type VGCC blockers, presents a promising therapeutic approach for breast cancer but more validation and clinical trials are needed. Also, for investigating the potential of T-type VGCC blocker therapy, there is a need for isoform-specific agonists/antagonists to define and discover roles of T-type VGCC specific isoforms.
Conclusion:
Our article provides a review of the role of T-type VGCCs in breast cancer and also discusses future of the research in this area so that it can be ascertained whether there is any potential of T-type VGCCs as drug targets in breast cancer.
Insights
T-type voltage-gated calcium channels (VGCCs) show potential as breast cancer drug targets. Research indicates VGCC antagonists inhibit growth, while CaV3.1 may suppress tumors, warranting further investigation for targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Breast cancer necessitates novel therapeutic strategies due to its high mortality rate across diverse molecular subtypes.
- Voltage-gated calcium channels (VGCCs) regulate intracellular calcium, influencing key cellular processes including tumorigenesis and cancer progression.
- T-type VGCCs have emerged as a focus in breast cancer research, with general calcium channel blockers demonstrating anti-proliferative and cytotoxic effects.
Purpose of the Study:
- To review the potential of T-type voltage-gated calcium channels (VGCCs) as viable drug targets for breast cancer treatment.
- To explore the role of specific T-type VGCC isoforms (CaV3.1 and CaV3.2) in breast cancer proliferation and tumor suppression.
- To discuss the implications of T-type VGCCs in breast cancer metastasis, epithelial-to-mesenchymal transition (EMT), and the potential of combination therapies.
Main Methods:
- Literature review of studies investigating T-type VGCCs in breast cancer.
- Analysis of research on the effects of T-type VGCC antagonists on cancer cell proliferation.
- Examination of findings related to CaV3.1 and CaV3.2 isoforms in breast cancer contexts.
Main Results:
- T-type VGCC antagonists exhibit anti-proliferative effects, particularly through CaV3.2 isoform inhibition.
- The CaV3.1 isoform shows promise as a tumor suppressor, supporting anti-proliferative and apoptotic activities in breast cancer.
- The distribution and specific roles of T-type VGCC isoforms in different breast cancer subtypes and metastatic processes require further elucidation.
Conclusions:
- T-type VGCCs represent a promising area for developing new breast cancer therapeutics.
- Further research, including isoform-specific studies and clinical trials, is essential to validate T-type VGCC blockers as a targeted therapy.
- Combination therapies involving chemotherapy and T-type VGCC blockers may offer a potent strategy for improving breast cancer treatment outcomes.
More Related Videos
Related Concept Videos
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Mechanically-gated Ion Channels
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
G-Protein Gated Ion Channels
Sensory...
Ligand-Gated Ion Channel Receptor: Gating Mechanism


